Postmenopausal Women With Osteoporosis Clinical Trial
Official title:
A Double-blind, Randomized, Active-controlled, Phase 3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis
This study is a Double-blind, Randomized, Active-controlled, Phase 3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of CT-P41 and US-licensed Prolia in Postmenopausal Women with Osteoporosis
This is a double-blind, randomized, active-controlled, Phase 3 study to evaluate the efficacy, PK, PD, and safety including immunogenicity of CT-P41 compared with US-licensed Prolia in postmenopausal women with osteoporosis. All patients will also receive daily supplementation containing at least 1,000 mg of elemental calcium and at least 400 IU vitamin D from randomization to EOS visit and the data will be collected via patient's diary. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01249261 -
Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover
|
Phase 3 | |
| Completed |
NCT01631214 -
Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis
|
Phase 3 | |
| Active, not recruiting |
NCT05345691 -
Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis
|
Phase 3 | |
| Active, not recruiting |
NCT05338086 -
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 [Proposed Denosumab Biosimilar] to Prolia® [EU-sourced] in Postmenopausal Osteoporosis (SIMBA Study)
|
Phase 3 | |
| Completed |
NCT03974100 -
Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis
|
Phase 3 | |
| Completed |
NCT01581320 -
Phase III Clinical Trial of DP-R206 and Bonvia In Postmenopausal Women With Osteoporosis
|
Phase 3 |